-
1 Comment
Hua Medicine (Shanghai) Ltd is currently in a long term downtrend where the price is trading 13.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has dropped by 15.8% to $-220M since the same quarter in the previous year.
Finally, its free cash flow grew by 188.7% to $73M since the same quarter in the previous year.
Based on the above factors, Hua Medicine (Shanghai) Ltd gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | HK |
| CurrencyCode | HKD |
| ISIN | KYG4644K1022 |
| Market Cap | 2B |
|---|---|
| PE Ratio | None |
| Target Price | 3.59 |
| Beta | 1.35 |
| Dividend Yield | None |
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. The company was incorporated in 2011 and is based in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2552.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
